10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2026)

10x Genomics (TXG) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 24.12% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $38.1 million (up 9.87% YoY), and the FY2025 full-year result was $36.2 million, up 0.89% from the prior year.
• Depreciation & Amortization (CF) retreated to $10.0 million in Q1 2026, from $10.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.3 million in Q3 2025 to a low of $6.2 million in Q3 2022.
• A 5-year average of $8.4 million and a median of $9.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 52.94% in 2023 and decreased 12.89% in 2025, its largest moves.
• Tracing TXG's Depreciation & Amortization (CF) over 5 years: stood at $6.5 million in 2022, then soared by 49.01% to $9.7 million in 2023, then retreated by 9.95% to $8.8 million in 2024, then climbed by 15.03% to $10.1 million in 2025, then decreased by 1.07% to $10.0 million in 2026.
• Business Quant data shows TXG's Depreciation & Amortization (CF) at $10.0 million in Q1 2026, $10.1 million in Q4 2025, and $10.3 million in Q3 2025.